Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like ParticlesPaul Goepfert, Harriet L. Robinson, Christine M. Hay et al.|The Journal of Infectious Diseases|2011Cited by 177
Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like ParticlesPaul Goepfert, Harriet L. Robinson, Marnie Elizaga et al.|The Journal of Infectious Diseases|2014Cited by 84
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adultsSusan Buchbinder, Nicole Grunenberg, Brittany Sanchez et al.|PLoS ONE|2017Cited by 33